Business
Exercise of Warrants, Issue of Equity & TVR
Exercise of Warrants, Issue of Equity & TVR.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3842U\n Futura Medical PLC\n 01 April 2021\n \n \n \n \n \n \n \n \n \n \n 1 April 2021\n \n \n \n Futura Medical plc\n \n \n \n \n Exercise of Warrants, Issue of Equity\n& Total Voting Rights\n \n \n Futura Medical plc (AIM: FUM) (\"Futura\" or the \"Company\"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today \n announces that it has received a warrant exercise notice from HT Riverwood Multi-Growth Fund (\"Riverwood\"), a fund managed by Atlantis Investment Management Limited (\"Atlantis\") in respect of 2,272,727 new ordinary shares of 0.2 pence in the Company (\"New Ordinary Shares\"), with an exercise price of 22 pence per share. Proceeds of £500,000 have been received by the Company in respect of the warrant exercise.\n \n \n Once issued, the New Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares of the Company.\n \n \n Application has been made for the 2,272,727 New Ordinary Shares to be admitted to trading on AIM (\"Admission\") and it is expected that Admission will occur on or about 7 April 2021.\n \n \n Total voting rights\n \n \n Following Admission, the Company's enlarged issued share capital will comprise 248,324,653 Ordinary Shares of 0.2 pence each, with one voting right per share (\"Ordinary Shares\"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 248,324,653.\n \n \n The above figure of 248,324,653 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n James Barder, Futura's Chief Executive, commented:\n \n \"I am appreciative of the continued support from Atlantis Investment Management Limited, which further strengthens the Company's cash position in preparation of future opportunities.\"\n \n \n The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abus...